0000000000199666

AUTHOR

Georgios Amvrosiadis

showing 8 related works from this author

CLINICAL OUTCOMES OF SELF-EXPAMDABLE METALLIC STENTS IN PALLIATION OF MALIGNANT ANASTOMOTIC STRICTURES: A SINGLE CENTER EXPERIENCE

2015

Background: self-expandable metallic stents (SEMS) are employed as the preferred non surgical palliative treatment for gastric outlet obstruction due to malignancies. Metallic stents are often employed to treat malignant anastomotic obstructions after surgicsl interventions as esophagojejunostomy, gastrojejunostomy and esophagogastrojejunostomy. Methods: this case series reports prospectively the clinical outcomes of SEMS in the palliative care of malignant anastomotic strictures caused by the recurrence gastric cancer follwing gastric surgery as oncological curative treatment, in a series of nine consecutive patients, treated between January 2009 and december 2012 in our center. Results: N…

MarketingPharmacologyOrganizational Behavior and Human Resource Managementmedicine.medical_specialtySettore MED/12 - GastroenterologiaPalliative treatmentbusiness.industryStrategy and Managementmedicine.medical_treatmentPharmaceutical ScienceStentGastric outlet obstructionAnastomosismedicine.diseaseSingle CenterSurgerySettore MED/18 - Chirurgia Generalegastric cancer palliation self-expandable metallic stent Billrot-II reconstruction.Self-expandable metallic stentDrug DiscoveryMedicineGastrectomyRadiologybusinessCovered stent
researchProduct

Superior Mesenteric Artery Syndrome: Clinical, Endoscopic, and Radiological Findings.

2018

Background. The superior mesenteric artery (SMA) syndrome is a rare entity presenting with upper gastrointestinal tract obstruction and weight loss. Studies to determine the optimal methods of diagnosis and treatment are required. Aims and Methods. This study aims at analyzing the clinical presentation, diagnosis, and management of SMA syndrome. Ten cases of SMA syndrome out of 2074 esophagogastroduodenoscopies were suspected. A contrast-enhanced computed tomography (CECT) scan was performed to confirm the diagnosis. After, a gastroenterologist and a nutritionist personalized the therapy. Furthermore, we compared the demographical, clinical, endoscopic, and radiological parameters of these …

medicine.medical_specialtyArticle Subject03 medical and health sciences0302 clinical medicineWeight lossInternal medicinemedicine.arterymedicineSuperior mesenteric arterylcsh:RC799-869Prospective cohort studySettore MED/12 - GastroenterologiaHepatologybusiness.industryGastroenterologyHepatologymedicine.diseaseSMA*Settore MED/18 - Chirurgia Generale030220 oncology & carcinogenesis030211 gastroenterology & hepatologylcsh:Diseases of the digestive system. GastroenterologyRadiologysuperior mesenteryc artery syndrome endoscopic finding radiological aspectsPresentation (obstetrics)medicine.symptombusinessBody mass indexSuperior mesenteric artery syndromeGastroenterology research and practice
researchProduct

An Unusual Presentation of Zollinger-Ellison Syndrome

2013

Abstract Zollinger-Ellison syndrome is an often progressive, persistent and frequently life-threatening disease, described for the first time as characterized by ulceration of the upper jejunum, hypersecretion of gastric acid and non-beta islet cell tumors of the pancreas; this syndrome is due to the hypersecretion of gastrin. We report a case of Zollinger-Ellison syndrome presenting as severe esophagitis evolving in stenosis, which demonstrates how a delayed diagnosis may induce risk of disease spreading. In this setting new diagnostic approaches, such as somatostatin receptor scanning and positron emission tomography with 68 Ga-labeled octreotide, could be particularly useful, as well as …

Positron emission tomographyPathologymedicine.medical_specialtySettore MED/09 - Medicina InternaOctreotideZollinger-Ellison syndromePublished online: January 2013medicinelcsh:RC799-869GastrinSomatostatin receptorbusiness.industryGastroenterologyZollinger ellison. severe esophagitismedicine.diseaseZollinger-Ellison syndromemedicine.anatomical_structureOctreoscanRadionuclide therapyGastric acidlcsh:Diseases of the digestive system. GastroenterologyEsophageal stricturesPancreasbusinessEsophagitismedicine.drugCase Reports in Gastroenterology
researchProduct

Efficacy of pneumatic dilatation for the treatment of idiopatic achalasia: a single-center experience

2015

Pneumatic dilatation (PD) and Surgical Miotomy (SM) are presently the best treatments for untreated achalasia, with similar efficacy. There is no information on the relative efficacy of PD in younger compared to older patients. Aim of our study was to compare success rate and safety of PD in patients under fifty years old and in those over fifty years old affected by achalasia. Twenty consecutive symptomatic patients were treated in our Unit with graded PD under fluoroscopic view. Five male and 15 female with a median age of 47 years were treated. Twelve patients were less than fifty years old (group I) while 8 were older (group II). Median dysphagia questionnaire score was 14 and13 ingroup…

MarketingPharmacologySettore MED/12 - GastroenterologiaOrganizational Behavior and Human Resource Managementmedicine.medical_specialtyRelative efficacybusiness.industryStrategy and ManagementGroup iiComplete remissionPharmaceutical ScienceAchalasiamedicine.diseaseSingle CenterDysphagiaSurgerySettore MED/18 - Chirurgia Generaleachalasia pneumatic dilatation esophageal obstructionOlder patientsDrug DiscoverymedicineIn patientmedicine.symptombusinessAbdomen
researchProduct

Heat shock proteins and ulcerative colitis: The start of a new era?

2015

Malemedicine.medical_specialtybusiness.industryGastroenterologyMEDLINEmedicine.diseaseUlcerative colitisGastroenterologySurgeryHeat shock proteinInternal medicineHumansMedicineColitis UlcerativeFemaleHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsIntestinal MucosaColitisbusinessPrecancerous ConditionsArab Journal of Gastroenterology
researchProduct

INFLAMMATION IN IRRITABLE BOWEL SYNDROME: MYTH OR NEW TREATMENT TARGET?

2016

Low-grade intestinal inflammation plays a key role in the pathophysiology of irritable bowel syndrome (IBS), and this role is likely to be multifactorial. The aim of this review was to summarize the evidence on the spectrum of mucosal inflammation in IBS, highlighting the relationship of this inflammation to the pathophysiology of IBS and its connection to clinical practice. We carried out a bibliographic search in Medline and the Cochrane Library for the period of January 1966 to December 2014, focusing on publications describing an interaction between inflammation and IBS. Several evidences demonstrate microscopic and molecular abnormalities in IBS patients. Understanding the mechanisms u…

Pathologymedicine.medical_specialtyMEDLINEAnti-Inflammatory AgentsInflammationCochrane LibraryBioinformaticsMast cell03 medical and health sciences0302 clinical medicineTreatment targetsGastrointestinal AgentsIntestinal inflammationmedicinePathologyAnimalsHumansMolecular Targeted TherapyTopic HighlightIntestinal MucosaIrritable bowel syndromeInflammationSettore MED/12 - GastroenterologiaMechanism (biology)business.industrySettore BIO/16 - Anatomia UmanaGastroenterologyGeneral MedicineInflammation; Irritable bowel syndrome; Mast cells; Neuroendocrine cells; Pathologymedicine.diseaseEnteritisClinical trialIrritable bowel syndromeSettore MED/18 - Chirurgia Generale030220 oncology & carcinogenesisNeuroendocrine cell030211 gastroenterology & hepatologymedicine.symptomInflammation Mediatorsbusiness
researchProduct

Does glatiramer acetate provoke hepatitis in multiple sclerosis?

2012

Abstract An association between multiple sclerosis and autoimmune hepatitis has been described. The latter can also be unmasked or exacerbated by a variety of therapies used in multiple sclerosis, such as beta-Interferon or glatiramer acetate. Two cases of hepatitis occurring after exposure to glatiramer acetate are described here: the first, was possibly due to autoimmune hepatitis, rather than glatiramer acetate induced liver injury, the second was definite autoimmune hepatitis. Both occurred in patients who had already experienced hepatitis exacerbations during previous beta-Interferon treatment. We suggest that glatiramer acetate can unmask hepatitis. Thus, liver enzyme monitoring shoul…

Liver injuryHepatitisbusiness.industryMultiple sclerosisGeneral MedicineAutoimmune hepatitismedicine.diseaseNeurologyInterferonLiver enzymeImmunologyMedicineIn patientNeurology (clinical)Glatiramer acetatebusinessmedicine.drugMultiple Sclerosis and Related Disorders
researchProduct

NEW THERAPEUTIC PERSPECTIVES IN IRRITABLE BOWEL SYNDROME: TARGETING LOW-GRADE INFLAMMATION, IMMUNO-NEUROENDOCRINE AXIS, MOTILITY, SDECRETION AND BEYO…

2017

Irritable bowel syndrome (IBS) is a chronic, recurring, and remitting functional disorder of the gastrointestinal tract characterized by abdominal pain, distention, and changes in bowel habits. Although there are several drugs for IBS, effective and approved treatments for one or more of the symptoms for various IBS subtypes are needed. Improved understanding of pathophysiological mechanisms such as the role of impaired bile acid metabolism, neurohormonal regulation, immune, dysfunction, the epithelial barrier and the secretory properties of the gut has led to advancements in the treatment of IBS. With regards to therapies for restoring intestinal permeability, multiple studies with prebiot…

Abdominal painmedicine.medical_specialtyReviewFunctional disorderGastroenterologyPermeabilityBile Acids and Salts03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGastrointestinal AgentsMesalazineInternal medicineImmunoendocrine axisTherapy; Low grade inflammation; Motility; Secretion; Irritable bowel syndrome; Immunoendocrine axismedicineHumansSecretionIrritable bowel syndromeInflammationClinical Trials as TopicGastrointestinal agentSettore MED/12 - GastroenterologiaLow grade inflammationIntestinal permeabilitybusiness.industryGastroenterologyMotilityDrugs InvestigationalGeneral Medicinemedicine.diseaseAbdominal PainRifaximinIntestinesClinical trialIrritable bowel syndromeSettore MED/18 - Chirurgia GeneraleTreatment Outcomechemistry030220 oncology & carcinogenesis030211 gastroenterology & hepatologyTherapymedicine.symptomGastrointestinal Motilitybusiness
researchProduct